Here, we report that NG29, and probably other synthetic biostable B1R agonists sharing the proper pharmacokinetic features [40], can be used as selective BTB modifiers to improve transvascular delivery of various-sized water soluble molecules to CNS tumors expressing substantial level of B1R. The gene discussed is BDKRB1; the disease is central nervous system neoplasm.